Synthesis, biological evaluation and molecular modeling studies of novel 1,2,3-triazole-linked menadione-furan derivatives as P2X7 inhibitors

J Bioenerg Biomembr. 2022 Dec;54(5-6):227-239. doi: 10.1007/s10863-022-09947-2. Epub 2022 Sep 7.

Abstract

The P2X7 receptor (P2X7R) is an ion channel that promotes the passage of ions through the membrane through brief stimulation once activated by ATP, its endogenous opener. However, prolonged stimulation with ATP, which occurs in pathological processes, opens a nonselective pore in the plasma membrane, allowing the passage of large molecules and leading to cytokine release or even cell death. In this sense, the search for new inhibitors for this receptor has attracted a great deal of attention in recent years. Considering the booming of biomass upgrading reactions in recent years and the continued efforts to synthesize biologically active molecules containing the 1,2,3-triazole ring, in the present work, we aimed to investigate whether triazole-linked menadione-furan derivatives could present P2X7R inhibitory activity. The novel compounds were tested for their inhibitory activity on ATP-induced dye uptake in peritoneal macrophages. Some have shown promising results, having displayed IC50 values lower than that of the P2X7R inhibitor BBG. Molecular docking studies also indicated that the active compounds bind to an allosteric site on P2X7R, presenting potential P2X7R inhibition.

Keywords: ATP; Azoles; Biomass; Heterocycles; Inflammation; Naphthoquinones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Furans / pharmacology
  • Molecular Docking Simulation
  • Purinergic P2X Receptor Antagonists / pharmacology
  • Receptors, Purinergic P2X7
  • Triazoles* / pharmacology
  • Vitamin K 3*

Substances

  • Vitamin K 3
  • Triazoles
  • Adenosine Triphosphate
  • Furans
  • Receptors, Purinergic P2X7
  • Purinergic P2X Receptor Antagonists